Peptides 101: What They Are, What Changed, and Where the Line Is

Peptides are everywhere right now: podcasts, gym locker rooms, your group chat. Most of that conversation is about what peptides might do. We think a more useful question gets far less airtime: where do they come from, and who’s preparing them? This Peptides 101 guide covers what peptides are, what just changed in federal policy, and where the line sits between a carefully prepared product and a risky one.

Quick Answer

Peptides are short chains of amino acids, and many occur naturally in the body. GLP-1 medications are peptides, for example. In wellness conversations, “peptides” often refers to emerging compounds such as BPC-157 and TB-500, and this guide focuses on the six covered by a new HHS policy. HHS has announced an interim policy describing when it won’t take enforcement action against qualifying compounders. That isn’t FDA approval, but it does open a more controlled path to access, through licensed pharmacies that meet the policy’s conditions.

Key Takeaways

• Peptides are short chains of amino acids. Your body makes thousands of them, and GLP-1 medications are peptides too.

• In wellness conversations, “peptides” often means emerging compounds such as BPC-157 and TB-500. Six of them are covered by a new HHS policy.

• HHS’s draft, interim enforcement-discretion policy describes conditions under which it doesn’t intend to take action against qualifying compounders. It isn’t FDA approval and doesn’t establish safety or effectiveness.

• There’s a clear line between research-use-only products mixed at home and peptides prepared by a licensed pharmacy.

• Peptides are coming to Trava, and we’re building that offering around sourcing, preparation, and provider guidance.

What Is a Peptide?

A peptide is a short chain of amino acids, the same building blocks that make up proteins. If proteins are full sentences, peptides are short phrases. Your body makes thousands of them, and many act as messengers that tell cells what to do.

You already know some peptides, even if you don’t think of them that way. Insulin is a peptide hormone. GLP-1 medications, like semaglutide and tirzepatide, are peptides too. So “peptides” isn’t a fringe category. It’s a big family that includes some of the most important medicines in use today.

What People Usually Mean by “Peptides” Right Now

In wellness conversations, “peptides” often refers to emerging compounds such as BPC-157 and TB-500. This guide focuses on the six covered by the HHS policy: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500.

These six compounds previously appeared in the FDA’s Category 2, which flagged potential significant safety risks in compounding. They were removed from that category in April 2026, but the removal didn’t, by itself, authorize compounding. HHS has since announced a separate interim enforcement-discretion policy describing conditions under which it doesn’t intend to take action against qualifying compounders. Meanwhile, demand never went away. Much of it moved online, to sellers offering “research-use-only” powders that buyers mix at home.

What Changed: The HHS Interim Peptide Policy

The U.S. Department of Health and Human Services (HHS) has announced a draft, interim enforcement-discretion policy covering those six peptides. In plain English: while the FDA works through formal rulemaking, HHS describes circumstances in which it doesn’t intend to take enforcement action against qualifying compounders who use them.

It’s worth being precise about what that means. The policy isn’t FDA approval, it isn’t binding, and it doesn’t establish that these peptides are safe or effective. What it does is set conditions, including tested ingredients from qualified manufacturers, single-ingredient products, specified routes, clear labeling, and safety reporting. HHS has said part of its goal is to steer people away from research-use-only products.

Where the Line Is

Here’s how we see the peptide landscape. On one side, there’s a corner of the wellness industry selling unverified products with big promises and little paperwork. On the other, there’s the traditional system, where access can depend on insurance, referrals, and long waits.

We think there’s a better third path: physician-guided telehealth access, with medications prepared by a licensed pharmacy.

So what does the right side of the line look like in practice? Here’s what to look for, wherever you get your peptides.

Where compounded peptides sit

Compounded peptides prepared under the policy are held to strict pharmacy requirements, but they haven’t gone through the FDA’s drug approval process, which evaluates evidence of safety and effectiveness along with manufacturing quality. That distinction is exactly why knowing who prepares your peptides, and how, matters so much.

What About the Benefits?

You’ve probably heard bold claims about what these peptides can do. Here’s the honest version: human research on all six is limited, and none is FDA-approved for any condition. Important questions remain about benefits, side effects, interactions, dosing, and long-term safety. That’s why we lead with how peptides are made and who’s guiding their use, not with promises.

Peptides Are Coming to Trava

We’re preparing to offer peptides the right way.

Trava is preparing to offer peptides through physician-guided telehealth, with medications prepared by our partner pharmacy, Optimal Balance, a licensed 503A pharmacy. We’re working to make sure our partner pharmacies meet the sourcing, documentation, and testing standards the HHS policy describes, as we prepare the offering for patients.

We’re not sharing dates or specific products yet. In the meantime, the most useful thing we can do is help you know what to look for, wherever you get your peptides.

Questions to Ask Before Starting Any Peptide

• Who prepares this peptide, and is it a state-licensed 503A pharmacy?

• Where does the raw ingredient come from, and is there a certificate of analysis?

• Will a licensed provider review my health history before I start?

• Is this a single-ingredient product for a route specified in the HHS policy?

• What does the research actually show, and what’s still unknown?

• What side effects should I watch for, and how do I report a problem?

Frequently Asked Questions

Are GLP-1 medications peptides?

Yes. GLP-1 medications such as semaglutide and tirzepatide are peptides: short chains of amino acids that act on specific receptors in the body. They’re a good reminder that peptides are a broad family. The six compounds in the news right now are a different group, and none of them is FDA-approved.

Are peptides FDA-approved?

Some are. Several peptide medications, including insulin and FDA-approved GLP-1 medications, have gone through the FDA’s approval process. The six peptides covered by HHS’s interim policy have not. Compounded versions prepared under the policy are not FDA-approved, which means the FDA hasn’t reviewed them for safety, effectiveness, or quality.

What does “research use only” mean?

Products labeled “for research use only” or “not for human consumption” aren’t intended for patient treatment. A seller’s purity report or professional packaging doesn’t establish that a product is suitable for human use. HHS cited the safety risks of research-use-only peptides as one reason for its interim policy.

When will Trava offer peptides?

We’re not sharing dates yet. We’re preparing to offer peptides through physician-guided telehealth and our partner pharmacy, Optimal Balance, and we’d rather get the details right than rush. We’ll share more as soon as we can.

The Bottom Line

Peptides are a big, important family of molecules, and the ones in the headlines right now just went through a meaningful regulatory shift. That shift isn’t FDA approval, and it doesn’t make every peptide product trustworthy. Sourcing, preparation, and provider involvement matter a lot, but they don’t answer the open questions about clinical safety and effectiveness.

Knowing where the line is puts you in a much better position to stay on the right side of it. We’ll keep sharing clear, honest guidance as the science and the rules evolve.

Sources and References

• HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. U.S. Department of Health and Human Services.

• Federal Register Notice on the Interim Peptide Compounding Policy. Federal Register, October 30, 2026.

• Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. U.S. Food and Drug Administration.

• Human Drug Compounding. U.S. Food and Drug Administration.

Last reviewed: November 2026

Disclaimer: This article is for general educational purposes and is not medical advice. Compounded medications are not FDA-approved. Talk with a licensed healthcare provider about your individual needs before starting, stopping, or changing any treatment.